In chest computed tomography (CT), the breasts located within the scan range receive a substantial radiation dose. Due to the risk of breast-related carcinogenesis, analyzing the breast dose for justification of CT examinations seems necessary. The main goal of this study is to overcome the limitations of conventional dosimetry methods, such as thermoluminescent dosimeters (TLDs) by introducing the adaptive neuro-fuzzy inference system (ANFIS) approach. In this study, the breast dose of 50 adult female patients who underwent chest CT examinations was measured directly by TLDs. Then, the ANFIS model was developed with four inputs including dose length product (DLP), volumetric CT dose index (CTDI), total mAs, and size-specific dose estimate (SSDE), and one output (TLD dose). Additionally, multiple linear regression (MLR) as a traditional prediction model was used for linear modeling and its results were compared with the ANFIS. The TLD reader results showed that the breast dose value was 12.37 ± 2.46 mGy. Performance indices of the ANFIS model, including root mean square error (RMSE) and correlation coefficient (R), were calculated at 0.172 and 0.93 for the testing dataset, respectively. Also, the ANFIS model had superior performance in predicting the breast dose than the MLR model (R = 0.805). This study demonstrates that the proposed ANFIS model is efficient for patient dose prediction in CT scans. Therefore, intelligence models such as ANFIS are suggested to estimate and optimize patient dose in CT examinations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225119 | PMC |
http://dx.doi.org/10.1007/s13246-023-01276-x | DOI Listing |
Acta Pharmacol Sin
January 2025
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Cancer heterogeneity, characterized by diverse populations of tumorigenic cells, involves the occurrence of differential phenotypes with variable expressions of receptor tyrosine kinases. Aberrant expressions of mesenchymal-epithelial transition (MET) and recepteur d'origine nantais (RON) receptors contribute to the phenotypic heterogeneity of cancer cells, which poses a major therapeutic challenge. This study aims to develop a dual-targeting antibody-drug conjugate (ADC) that can act against both MET and RON for treating cancers with high phenotypic heterogeneity.
View Article and Find Full Text PDFClin Breast Cancer
December 2024
Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
Purpose: There is limited data on the use of low dose tamoxifen (LDT) for chemoprevention since its introduction in 2019. This study sought to determine the rate of LDT uptake at our institution and describe factors associated with its use.
Methods: We performed a retrospective chart review of women diagnosed with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and/or atypical hyperplasia from 2019 to 2021.
Med Phys
January 2025
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Background: Dedicated breast computed tomography (bCT) systems offer detailed imaging for breast cancer diagnosis and treatment. As new bCT generations are developed, it is important to evaluate their imaging performance and dose efficiency to understand differences over previous models.
Purpose: To characterize the imaging performance and dose efficiency of a second-generation (GEN2) bCT system and compare them to those of a first-generation (GEN1) system.
Cureus
December 2024
Medical Affairs, Zydus Lifesciences, Ahmedabad, IND.
Background Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a highly aggressive subtype characterized by a high recurrence rate. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, has shown improved outcomes; however, its effectiveness in cases with brain metastases remains unclear. The T-DM1 biosimilar has emerged as a cost-effective treatment option.
View Article and Find Full Text PDFCureus
December 2024
Anaesthesiology, All India Institute of Medical Sciences, Raipur, Raipur, IND.
Introduction: Breast cancer is the most common cancer in females. Surgery is the gold standard therapy, with modified radical mastectomy (MRM) being the most commonly performed procedure for breast cancer. Management of postoperative pain after MRM poses a clinical challenge and hence receives utmost priority.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!